Researchers suggest that avoiding light at night may be a useful strategy to reduce cardiovascular disease risk.

KING OF PRUSSIA, PA — XyloCor Therapeutics has dosed the first patient in its Phase 2b EXACT-2 trial evaluating XC001 (encoberminogene rezmadenovec), a novel gene therapy designed to help patients ...

It’s as if sudden cardiac arrest is met with a resigned shrug: If it’s nearly impossible to predict and even harder to treat, ...

Silent graft occlusion after coronary artery bypass grafting is detected before hospital discharge and is linked to ...

A new AI algorithm developed by researchers from the University of Western Australia has been found to better predict the ...

Medtronic's Jason Fontana offers an update on next-generation Symplicity Spyral devices, procedures and a new feature they're ...

Does colchicine work for CVD or doesn’t it? That’s the question the study authors hoped to answer, but there’s little ...

PlaqueIQ is the first and only FDA-cleared, non-invasive plaque analysis based on objective histology. PlaqueIQ delivers automated quantification and classification of plaque morphology, and is ...

A study was conducted to determine the relationship between gestational diabetes and prepregnancy cardiovascular health and midlife subclinical CVD.

The company will distribute its naloxone spray to more than 1,000 sites across Michigan through its dedicated portal.

Japan's 91-year-old former Emperor Akihito has been hospitalized to adjust his heart medication, palace officials say. He was ...

Japan's 91-year-old former Emperor Akihito has been hospitalized to adjust his heart medication, palace officials say.